Tags : Provides

Clinical Trials

Voyager Therapeutics Provides Update on NBIB-1817 (VY-AADC) Program to Treat

Shots: The P-ll RESTORE-1 study involves assessing NBIb-1817(VY-AADC) for the treatment of Parkinson’s disease. Neurocrine & Voyager will closely work with FDA & DCMB to determine the next clinical trial for RESTORE-1 DSMB request a clinical hold, follows the IND Safety Report submit by Neurocrine Biosciences related to the observation of MRI abnormalities in some […]Read More